Biogen (NASDAQ:BIIB) Target Lowered by Morgan Stanley to $447.00

Biogen stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by Morgan Stanley on 10/12/2021. In a note to investors, the firm issued a new target price of $447.00. The analysts previously had $455.00 target price. Morgan Stanley’s price target would indicate a potential upside of 56.52% from the stock’s previous close.

Shares of traded on monday, reaching $287.12. 80763 shares of the stock traded hands, compared to its average volume of 1010613. On monday, Shares of closed at $287.12. The firm’s 50 day moving average is 317.07 and its 200 day moving average is 298.61.  has a 12 month low of $223.25 and a 12 month high of $468.55. While on yearly highs and lows, today has traded high as $287.50 and has touched $283.85 on the downward trend.

Earnings and What to expect: 

Biogen last posted its earnings data on July 21st, 2021. The biotechnology company reported $5.68 earnings per share for the quarter, topping analysts’ consensus estimates of $4.55 by $1.13. The company had revenue of $2.78 billion for the quarter, compared to analysts’ expectations of $2.61 billion. Its quarterly revenue was down 24.6% on a year-over-year basis. Biogen has generated $33.70 earnings per share over the last year ($12.46 diluted earnings per share) and currently has a price-to-earnings ratio of 22.9. Earnings for Biogen are expected to grow by 11.57% in the coming year, from $18.67 to $20.83 per share. Biogen has confirmed that its next quarterly earnings report will be published on Wednesday, October 20th, 2021. Biogen will be holding an earnings conference call on Wednesday, October 20th at 8:00 AM Eastern. Interested parties can .

Earnings for Biogen are expected to grow by 11.57% in the coming year, from $18.67 to $20.83 per share. The P/E ratio of Biogen is 22.92, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.28. The P/E ratio of Biogen is 22.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.17. Biogen has a PEG Ratio of 1.54. PEG Ratios above 1 indicate that a company could be overvalued. Biogen has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

(NASDAQ:BIIB) Moving Average Technical Analysis

5 day Moving Average is $284.64 And 5 day price change is 7.27 (2.61%)  with average volume for 5 day average is 823,840. While technical analysis for average 20 days shows significant difference, 20 day moving average is  289.43 and 20 day price change is -16.35 (-5.41%) and average 20 day moving volume is 918,895. 50 day moving average is 317.07  and 50 day price change is -41.14 ( -12.59%)  and with average volume for 50 days is : 949,962. 200 day moving average is 298.61  and 200 day price change is 34.39 (13.69%)  and with average volume for 200 days is : 1,395,270.

Other owners latest trading in Biogen :

  • On 10/8/2021 shares held by Timber Creek Capital Management LLC were 15,375 which equates to market value of $4.35M and appx 1.40% owners of Biogen
  • On 10/8/2021 shares held by FDx Advisors Inc. were 3,306 which equates to market value of $0.94M and appx 0.00% owners of Biogen
  • On 10/8/2021 shares held by Cullinan Associates Inc. were 3,754 which equates to market value of $1.06M and appx 0.10% owners of Biogen
  • In total Institutional ownership equates to Institutional Ownership Percentage: 83.18% for Biogen

See More Analyst Rating at: RATING